RxDoctor Payments Data

Scott Segal, MD

Ophthalmology · Pasadena, TXNPI 1154373942

Payments from drug & device makers

$2,643in general payments, 2019–2025

Across 126 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$709
  • Alcon$486
  • Sun Pharmaceutical Industries Inc.$367
  • Oyster Point Pharma, Inc.$173
  • Kala Pharmaceuticals, Inc.$147
  • Novartis$144
  • plus $617 from 14 others

What the payments were for

  • Food & beverage$2,57697%
  • Education$482%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,643 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$246,976
Medicare patients
969
Services billed
2,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine78$113,233
LumiganBimatoprost95$56,558
XiidraLifitegrast20$36,175
CombiganBrimonidine Tartrate/Timolol65$32,753
Alphagan PBrimonidine Tartrate47$20,423
MieboPerfluorohexyloctane/Pf13$9,850
SimbrinzaBrinzolamide/Brimonidine Tart30$8,367
VyzultaLatanoprostene Bunod24$8,331
Latanoprost779$7,692
Brimonidine Tartrate69$7,246
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$6,870
RhopressaNetarsudil Mesylate14$4,634
Travoprost45$4,286
AlrexLoteprednol Etabonate14$4,120
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha382$4,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$709$222,967285 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$97$54,35657 claims
AlconSimbrinza$486$8,36730 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex$76$4,12014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →